Apellis Pharmaceuticals Is Maintained at Outperform by Baird

Dow Jones01:51 · Ratings

Apellis Pharmaceuticals Analyst Ratings

Benzinga01:39 · Ratings

UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45

Futu NewsNov 7 21:31 · Ratings

A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55

Futu NewsNov 7 21:00 · Ratings

Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise

InvestingNov 7 16:24

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24

BenzingaNov 7 00:13 · Ratings